1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Novartis blocks generic Galvus launch in India

 
• By Sukaina Virji

Novartis in India has blocked generic firm Wockhardt from launching copies of Galvus (vildagliptin), its DPP-4 inhibitor for diabetes.

Novartis in India has blocked generic firm Wockhardt from launching copies of Galvus (vildagliptin), its DPP-4 inhibitor for diabetes.

The Delhi High Court has ordered Wockhardt to stop selling or exporting formulations of vildagliptin or combinations of vildagliptin and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

Amycretin Heads For Phase III In Type 2 Diabetes

 
• By Joseph Haas

New Phase II data in type 2 diabetes for Novo Nordisk’s GLP-1/amylin agonist amycretin shows significant weight loss and HbA1c-lowering potential. A Phase III trial is planned.

Jefferies 25: The Cardiometabolic Revolution Is Going Global

 
• By Andrew McConaghie

Madrigal, Wave Therapeutics and Kailera are in the next wave of cardiometabolic therapy companies, and at Jefferies talked about how US and China-derived innovation can help reach more patients in the US and the rest of the world.

Vanda Moves Drug For GLP-1 Nausea And Vomiting Into Phase III

 
• By Alaric DeArment

The company announced positive Phase II results for tradipitant among patients taking Wegovy, enabling them to move more quickly to a therapeutic dose, when patients normally need to titrate.

Obesity Beyond GLP-1s: Combinations And Multiple Agonists Keep The Charge Going

 
• By Aakash Babu

In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years.

More from Therapy Areas

Lundbeck Concedes Avadel Bidding War, But Remains On The Hunt

 
• By Manas Mishra

Lundbeck does not plan to raise its offer for sleep specialist Avadel, clearing the way for Alkermes to win the two-way bidding war.

AstraZeneca Scores FDA Win For Imfinzi In Perioperative Stomach Cancer

 
• By Alaric DeArment

The agency’s approval of Imfinzi combined with chemotherapy makes it the only immunotherapy for perioperative gastric and gastroesophageal cancers.

Satellos Tackles Duchenne ‘As Stem Cell People Solving a Stem Cell Problem’

 
• By Manas Mishra

Satellos is moving to start a double-blinded Phase II trial of its experimental Duchenne muscular dystrophy candidate that looks to mimic the effects of dystrophin on muscle stem cells.